Optical

Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases

Thursday, August 5, 2021 - 9:01pm

Under a 2020 amendment, the Company and Regenerons efforts have focused on research and development of an extended-delivery formulation of aflibercept to be delivered to the suprachoroidal space for the treatment of retinal diseases.

Key Points: 
  • Under a 2020 amendment, the Company and Regenerons efforts have focused on research and development of an extended-delivery formulation of aflibercept to be delivered to the suprachoroidal space for the treatment of retinal diseases.
  • Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology.
  • Ocular Therapeutixs first commercial drug product, DEXTENZA, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery.
  • Ocular Therapeutix's first product, ReSure Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.

Visus Therapeutics to Host First Capital Markets Day in New York City on August 31, 2021

Thursday, August 5, 2021 - 4:42pm

Presenters will share new data including market sizing and market research insights from consumers and health care providers.

Key Points: 
  • Presenters will share new data including market sizing and market research insights from consumers and health care providers.
  • There will be moderated Q&A sessions and opportunities for media to speak with Visus Therapeutics executives and leading medical experts.
  • To register for the event, please visit the Visus 2021 Capital Markets Day registration site .
  • Visus Therapeutics is a clinical-stage company focused on developing innovative ophthalmic therapies to improve vision for people around the world.

Heru, the Wearable Diagnostic and Vision Augmentation Leader, Launches Commercial Availability of re:Vive in Partnership with Vision Source

Thursday, August 5, 2021 - 3:00pm

Heru Inc. , the innovator of the vision diagnostics and augmentation platform, announced in partnership with its worldwide launch partner, Vision Source , the commercial availability of re:Vive, its wearable diagnostics and visual field application.

Key Points: 
  • Heru Inc. , the innovator of the vision diagnostics and augmentation platform, announced in partnership with its worldwide launch partner, Vision Source , the commercial availability of re:Vive, its wearable diagnostics and visual field application.
  • re:Vive will transform the waiting room, enable physicians to use an existing pre-test space, or perform diagnostic exams between practices or even remote locations.
  • We are thrilled to be Herus worldwide launch partner, said Dr. John McCall, Sr. Vice President, Vision Source.
  • Heru is the only cross-platform solution with patents to autonomously diagnose vision defects and customize individual vision augmentation based on the users unique vision defects.

Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights

Thursday, August 5, 2021 - 12:00pm

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today reported financial results for the quarter ended June 30, 2021 and recent corporate highlights.

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today reported financial results for the quarter ended June 30, 2021 and recent corporate highlights.
  • ET today to discuss second-quarter 2021 financial results and recent corporate highlights.
  • After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.
  • Aldeyra Therapeutics is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases.

LENSAR Reports Second Quarter 2021 Financial Results and Provides Business Update

Thursday, August 5, 2021 - 12:00pm

For the quarter ended June 30, 2021, approximately 90% of our revenue was attributable to recurring sources compared to 78% for the quarter ended June 30, 2020.

Key Points: 
  • For the quarter ended June 30, 2021, approximately 90% of our revenue was attributable to recurring sources compared to 78% for the quarter ended June 30, 2020.
  • Cash utilized in the quarter ended June 30, 2021 was $1.3 million and $6.0 million for first half of 2021.
  • LENSAR management will host a conference call and live webcast to discuss the second quarter results and provide a business update today, August 5, 2021 at 8:30 a.m.
  • It uses these non-GAAP financial measures in order to have comparable financial results to analyze changes in its underlying business from quarter to quarter.

Encellin Closes $5.9M Seed Financing Co-Led by Khosla Ventures and SV Latam Capital

Thursday, August 5, 2021 - 1:00pm

The round was co-led by Khosla Ventures and SV Latam Capital, with participation from Sandhill Angels and Y Combinator.

Key Points: 
  • The round was co-led by Khosla Ventures and SV Latam Capital, with participation from Sandhill Angels and Y Combinator.
  • The financing will also be used to build out the laboratory and also expand the team.
  • Encellin will also expand into areas with readily available renewable cell sources and engineered cells, to encapsulate any cellular cargo in products from its proprietary platform.
  • The companys technology combines ad novel cell encapsulation technology with functional cell therapies to treat chronic diseases, starting with endocrine disorders.

NovaBay Pharmaceuticals to Hold Second Quarter 2021 Conference Call on August 12

Thursday, August 5, 2021 - 11:50am

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces it will report financial results for the three and six months ended June 30, 2021 after market close on Thursday, August 12, 2021 and will hold an investment community conference call that day at 4:30 p.m. Eastern time.

Key Points: 
  • NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces it will report financial results for the three and six months ended June 30, 2021 after market close on Thursday, August 12, 2021 and will hold an investment community conference call that day at 4:30 p.m. Eastern time.
  • Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator.
  • Participants may pre-register at any time, including up to and after the call start time.
  • Those who choose not to pre-register can access the live conference call by dialing the following and requesting the NovaBay Pharmaceuticals call:
    866-777-2509 from within the U.S.
    412-317-5413 from outside the U.S.

Global Dry Eye Disease Drug Pipeline Research Report 2021 - ResearchAndMarkets.com

Thursday, August 5, 2021 - 8:35am

The "Dry Eye Disease - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dry Eye Disease - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This Dry Eye Disease - Pipeline Insight, 2021 provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Dry Eye Disease pipeline landscape.
  • The U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease.
  • The companies which have their Dry Eye Disease drug candidates in the most advanced stage, i.e.